首页> 外文期刊>Urology >Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
【24h】

Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.

机译:比较电刺激和奥昔布宁氯化物治疗膀胱过度活动症(特别是尿急)的比较:一项随机安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To compare the efficacy of electric stimulation (ES), oxybutynin, and placebo in managing the symptom complex of overactive bladder (OAB), particularly urgency. METHODS: A randomized placebo-controlled trial was conducted for 68 patients with OAB, placing emphasis on urinary urgency. The interventions for the 12-week treatment period, conducted by the physiotherapist, who was unaware of the progress and outcome, included a vaginal ES program using biphasic symmetric, pulsed current with a 10-Hz frequency, 400-micros pulse width, 10/5 duty cycle, and varying intensity; and oxybutynin (2.5 mg) or placebo three times per day. Identical preintervention and postintervention assessments included the measurement of warning time, urodynamics, voiding diaries, and King's Health Questionnaire. RESULTS: Of the 68 women who completed this study, 24 were in the ES, 23 in the oxybutynin, and 21 in the placebo group. The between-group comparison showed that significant improvements in daily voided volume,pad count, number of urgency and nocturia episodes, and the domain 2 score and total score of the King's Health Questionnaire existed between the ES and the other groups (all P < or = 0.050). The changes in warning time, maximal voided volume, number of urgency episodes, and frequency were significantly improved between oxybutynin and placebo (all P < 0.013). Additionally, a comparison of the voided volume in uroflowmetry between the ES and placebo groups revealed a greater difference after treatment (P = 0.013). The reduction rate of OAB was 58.4% for the ES, 39.1% for the oxybutynin, and 9.5% for the placebo group (P = 0.036). CONCLUSIONS: ES had the greatest subjective outcome for OAB and was the most effective of the three treatments. Oxybutynin was more effective than placebo.
机译:目的:比较电刺激(ES),奥昔布宁和安慰剂在治疗膀胱过度活动症(OAB)症状复合体(特别是紧急情况)中的功效。方法:对68例OAB患者进行了一项随机安慰剂对照试验,重点是尿急。由理疗师进行的为期12周治疗的干预措施并不知道进展和结果,其中包括使用双相对称脉冲电流,频率为10 Hz,脉冲宽度为400 micros,频率为10 / 5个占空比,并且强度变化;和奥昔布宁(2.5毫克)或安慰剂,每天3次。相同的干预前和干预后评估包括警告时间,尿流动力学,排尿日记和King's Health问卷的测量。结果:完成这项研究的68位女性中,有24位在ES中,奥昔布宁为23位,安慰剂组为21位。组间比较显示,ES和其他组之间的每日排尿量,尿垫数量,尿急和夜尿次数以及King's Health问卷的领域2得分和总得分均有显着改善(所有P <或= 0.050)。奥昔布宁和安慰剂之间的警告时间,最大排尿量,尿急发作次数和频率的变化均得到了显着改善(所有P <0.013)。此外,ES组和安慰剂组之间在尿流测定中的排尿体积比较显示治疗后差异更大(P = 0.013)。 ES的OAB降低率为58.4%,奥昔布宁为39.1%,安慰剂组为9.5%(P = 0.036)。结论:ES对于OAB具有最大的主观结果,并且是三种治疗中最有效的。奥昔布宁比安慰剂更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号